Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

93 Percent of Nucleoside-Naive Chronic Hepatitis B e-Antigen (HBeAg)-Negative Patients Achieved Undetectable Viral Load by Week 48 of Re-Treatment

PRINCETON, N.J., April 13, 2007 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced data from a cohort of nucleoside-naive HBeAg-negative chronic hepatitis B patients (ETV-027/901, n=99). These data showed that patients who experienced recurrent levels of hepatitis B virus in the blood after interruption of treatment with BARACLUDE(R) (entecavir) achieved viral suppression and liver enzyme (ALT) normalization when re- treated for 48 weeks with BARACLUDE. The study results were presented at the 42nd Annual Meeting of the European Association for the Study of Liver Diseases (EASL) in Barcelona, Spain.

In this cohort, 93 percent of patients who were re-treated with BARACLUDE had undetectable viral load - the level of the hepatitis B virus in the blood - (HBV DNA <300 copies/mL, measured by a common assay - polymerase chain reaction or PCR) and 83 percent achieved liver enzyme normalization (ALT less than or equal to 1xULN) after 48 weeks of therapy.

"This study showed that when treated again with BARACLUDE for 48 weeks, patients achieved responses similar to those seen prior to treatment interruption, with safety results consistent with previously reported experience," said Hakan Senturk, MD, of the Ist.Univ.Cerrahpasa Tip Fak, Istanbul, Turkey.

No deaths or treatment discontinuations due to adverse events were reported in this cohort. The most common adverse events occurring in greater than 10 percent of patients were abdominal pain, fatigue, upper respiratory tract infection, nasopharyngitis, increased ALT, arthralgia, and headache.

About the Nucleoside-Naive HBeAg-Negative BARACLUDE(R) (entecavir) Re- Treatment Cohort

This analysis evaluated BARACLUDE(R) (entecavir) in nucleoside-naive chronic HBeAg-negative patie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:9/3/2015)... Mass. , Sept. 3, 2015 ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that its President and Chief Executive Officer, ... the 2015 Wells Fargo Healthcare Conference at 8:50 a.m. ... held Sept. 9-10, 2015 at The Hyatt Regency, ...
(Date:9/3/2015)... PLEASANTON, Calif. , Sept. 3, 2015 /PRNewswire/ ... detailed in a white paper released by ... the Agency for Healthcare Research & Quality (AHRQ), ... an estimated $9.1-$11.6 billion annually . In addition ... result in litigation, government penalties, and negatively impact ...
(Date:9/3/2015)... Sept. 3, 2015  Omeros Corporation (NASDAQ: OMER ... lawsuits against Par Pharmaceutical, Inc. and its subsidiary, Par ... Court for the District of New Jersey ... the District of Delaware . The ... infringement of three Omeros patents, U.S. Patent Nos. 8,173,707, ...
Breaking Medicine Technology:HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3Omeros Files Infringement Suits Against Par 2Omeros Files Infringement Suits Against Par 3Omeros Files Infringement Suits Against Par 4
... Reveals Shift in Prescribing Patterns As More MDs ... of Cholesterol-Reducing Drug, NEW YORK, Feb. 7 ... trial results on January 14, 2008,physicians are less concerned ... results than they were initially, according to a pivotal ...
... SAN FRANCISCO, Calif., Feb. 7 Researchers ... annual meeting,showing that training on the Posit ... cancer patients with "chemobrain". "Chemobrain",is a condition ... It affects quality of life by impairing ...
Cached Medicine Technology:Physicians Reconsider Implications of Enhance Trial 2Neuroscientists Offer Hope for Breast Cancer Patients Suffering From 'Chemobrain' 2
(Date:9/3/2015)... ... September 03, 2015 , ... Advice columnist, professional ... her debut book, “Stop Wasting Your Time Blaming Others for Your Life.” , ... guide to overcoming life’s obstacles by taking full responsibility for one’s life shares ...
(Date:9/3/2015)... ... 03, 2015 , ... Girl’s Night Out to benefit Core Compassion Project will ... Kate Road in Monroe, North Carolina. The event food will be provided ... Kate Clyde’s offers off-premise catering and event services from casual to elegant. They are ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... included Intellicure, Inc., in its Annual Inc. 5000 list of fastest-growing private ... that "only a tiny fraction of the nation's companies have demonstrated such remarkably ...
(Date:9/3/2015)... ... September 03, 2015 , ... B. ... has been retained to lead a national chief executive officer recruitment ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology Nurse Advisor article ... help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated for ... by HPV infections, which have a high rate of success in treatment and elimination ...
Breaking Medicine News(10 mins):Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3
... an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University,s ... L803-MTS, to treat a number of central nervous system ... shows promise against Parkinson,s, Huntington,s and diabetes. ... GSK3 protein, which plays a causative role in insulin ...
... a family involved in several human diseases is crucial ... research has found, suggesting that the protein might play ... channel, a passageway that allows negatively-charged chloride ions to ... insulin of normal mice, according to research published this ...
... , MONDAY, Oct. 26 (HealthDay News) -- Black women ... a breast abnormality, a U.S. study has found. , ... is detected at a later stage, which may reduce ... at the University of South Carolina in Columbia analyzed ...
... heart from complications of extra weight, study finds, , ... that you can be both fat and fit, new ... have some risk factors for heart disease. , ... and major league baseball players, researchers found that football ...
... ... ... 26, 2009 -- Safety Management Services, Inc. (SMS, Inc.), a Chicago-based healthcare ... examination. Developed in support of the Certified Healthcare Emergency Professional (CHEP) certification , ...
... R.I., Oct. 26 According to The ... are used in the U.S. each year, and only roughly ... encourage shoppers to cut down on the use of single-use ... called GreenBagTag which rewards members of the company,s ...
Cached Medicine News:Health News:A nervous system drug-by-design 2Health News:Protein critical for insulin secretion may be contributor to diabetes 2Health News:Protein critical for insulin secretion may be contributor to diabetes 3Health News:Breast Abnormality Follow-Up Often Later in Black Women 2Health News:Big, Beefy Football Players May Face Heart Problems Later 2Health News:Big, Beefy Football Players May Face Heart Problems Later 3Health News:Safety Management Services, Inc. Develops New Regional Preparation Course And Exam For CHEP Certification 2Health News:Safety Management Services, Inc. Develops New Regional Preparation Course And Exam For CHEP Certification 3Health News:CVS/pharmacy Rewards Shoppers For Passing on Plastic Bags 2Health News:CVS/pharmacy Rewards Shoppers For Passing on Plastic Bags 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: